PURPOSE: To describe the psychometric properties and identify the minimally important difference (MID) of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument. Chronic HCV infection and associated treatments negatively affect PROs of function and well-being. METHODS: In a phase 2 trial, HCV-infected patients received direct-acting antivirals (DAAs) for 12 weeks with peg-interferon/ribavirin (peg-IFN/RBV) for 48 weeks, or placebo plus peg-IFN/RBV. The HCV-PRO total score, SF-36 PCS and MCS scores, EQ-5D-3L, and EQ VAS were measured at baseline, week 8, end of DAA treatment (EODT), end of peg-IFN/RBV treatment (EOT), and posttreatment week 24 (SVR24). Convergent validity of the HCV-PRO was assessed by Pearson's correlation coefficients. Discriminant validity was assessed by analyzing mean HCV-PRO total scores by EQ-5D anxiety/depression and pain/discomfort domain scores (none vs. some) and presence/absence of depression or fatigue adverse events. MID was identified through effect size (ES) and receiver-operating characteristic (ROC) curve analyses (HCV-PRO response vs. SF-36 PCS/MCS and EQ VAS MID thresholds). RESULTS: In 74 patients (22 % female; 81 % White; 51 % ≥50 years), correlations (0.64-0.96) between HCV-PRO total scores, SF-36 PCS/MCS scores, and EQ VAS scores at all time points supported convergent validity. HCV-PRO total scores were reduced to 10-30 points in patients impaired by depression, pain, or fatigue symptoms. Impact of peg-IFN/RBV regimen on HCV-PRO ES increased over time (EODT -0.76; EOT -0.93). ES and ROC curve analyses indicated an MID of -10 points. CONCLUSION: The HCV-PRO was valid and responsive in the population studied. An MID of -10 points represented a threshold of clinical significance for the HCV-PRO.
RCT Entities:
PURPOSE: To describe the psychometric properties and identify the minimally important difference (MID) of the hepatitis C viruspatient-reported outcomes (HCV-PRO) instrument. Chronic HCV infection and associated treatments negatively affect PROs of function and well-being. METHODS: In a phase 2 trial, HCV-infectedpatients received direct-acting antivirals (DAAs) for 12 weeks with peg-interferon/ribavirin (peg-IFN/RBV) for 48 weeks, or placebo plus peg-IFN/RBV. The HCV-PRO total score, SF-36 PCS and MCS scores, EQ-5D-3L, and EQ VAS were measured at baseline, week 8, end of DAA treatment (EODT), end of peg-IFN/RBV treatment (EOT), and posttreatment week 24 (SVR24). Convergent validity of the HCV-PRO was assessed by Pearson's correlation coefficients. Discriminant validity was assessed by analyzing mean HCV-PRO total scores by EQ-5D anxiety/depression and pain/discomfort domain scores (none vs. some) and presence/absence of depression or fatigue adverse events. MID was identified through effect size (ES) and receiver-operating characteristic (ROC) curve analyses (HCV-PRO response vs. SF-36 PCS/MCS and EQ VAS MID thresholds). RESULTS: In 74 patients (22 % female; 81 % White; 51 % ≥50 years), correlations (0.64-0.96) between HCV-PRO total scores, SF-36 PCS/MCS scores, and EQ VAS scores at all time points supported convergent validity. HCV-PRO total scores were reduced to 10-30 points in patientsimpaired by depression, pain, or fatigue symptoms. Impact of peg-IFN/RBV regimen on HCV-PRO ES increased over time (EODT -0.76; EOT -0.93). ES and ROC curve analyses indicated an MID of -10 points. CONCLUSION: The HCV-PRO was valid and responsive in the population studied. An MID of -10 points represented a threshold of clinical significance for the HCV-PRO.
Authors: Marco DaCosta DiBonaventura; Jan-Samuel Wagner; Yong Yuan; Gilbert L'Italien; Paul Langley; W Ray Kim Journal: J Med Econ Date: 2010-11-22 Impact factor: 2.448
Authors: I M Gralnek; R D Hays; A Kilbourne; H R Rosen; E B Keeffe; L Artinian; S Kim; D Lazarovici; D M Jensen; R W Busuttil; P Martin Journal: Am J Gastroenterol Date: 2000-12 Impact factor: 10.864
Authors: Brennan M R Spiegel; Zobair M Younossi; Ron D Hays; Dennis Revicki; Sean Robbins; Fasiha Kanwal Journal: Hepatology Date: 2005-04 Impact factor: 17.425
Authors: Roger T Anderson; Robert W Baran; Birgitta Dietz; Eric Kallwitz; Pennifer Erickson; Dennis A Revicki Journal: Qual Life Res Date: 2013-09-05 Impact factor: 4.147
Authors: Vibeke Strand; Maarten Boers; Leanne Idzerda; John R Kirwan; Tore K Kvien; Peter S Tugwell; Maxime Dougados Journal: J Rheumatol Date: 2011-08 Impact factor: 4.666
Authors: Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward Journal: MMWR Recomm Rep Date: 2012-08-17
Authors: Donna M Evon; Carol E Golin; Paul Stewart; Michael W Fried; Shani Alston; Bryce Reeve; Anna S Lok; Richard K Sterling; Joseph K Lim; Nancy Reau; Souvik Sarkar; David R Nelson; K R Reddy; Adrian M Di Bisceglie Journal: Contemp Clin Trials Date: 2017-03-22 Impact factor: 2.226
Authors: D M Evon; J Amador; P Stewart; B B Reeve; A S Lok; R K Sterling; A M Di Bisceglie; N Reau; M Serper; S Sarkar; J K Lim; C E Golin; M W Fried Journal: Aliment Pharmacol Ther Date: 2018-01-29 Impact factor: 8.171
Authors: Donna M Evon; Souvik Sarkar; Jipcy Amador; Anna S Lok; Richard K Sterling; Paul W Stewart; Bryce B Reeve; Marina Serper; Nancy Reau; K Rajender Reddy; Adrian M Di Bisceglie; David R Nelson; Carol E Golin; Joseph K Lim; Michael W Fried Journal: J Hepatol Date: 2019-05-13 Impact factor: 30.083
Authors: Andrew Richard Armstrong; Susan Elizabeth Herrmann; Olivier Chassany; Christophe Lalanne; Mariliza Henrique Da Silva; Eliana Galano; Patrizia M Carrieri; Vincent Estellon; Philippe Sogni; Martin Duracinsky Journal: BMC Infect Dis Date: 2016-08-23 Impact factor: 3.090
Authors: Donna M Evon; Paul W Stewart; Jipcy Amador; Marina Serper; Anna S Lok; Richard K Sterling; Souvik Sarkar; Carol E Golin; Bryce B Reeve; David R Nelson; Nancy Reau; Joseph K Lim; K Rajender Reddy; Adrian M Di Bisceglie; Michael W Fried Journal: PLoS One Date: 2018-08-01 Impact factor: 3.240
Authors: Marina Serper; Donna M Evon; Jipcy Amador; Paul W Stewart; Souvik Sarkar; Anna S Lok; Richard K Sterling; Bryce B Reeve; Carol E Golin; K Rajender Reddy; Joseph K Lim; Nancy Reau; David R Nelson; Adrian M Di Bisceglie; Michael W Fried Journal: Liver Int Date: 2021-01-22 Impact factor: 5.828